Dianthus Therapeutics, Inc.
DNTH
$24.33
$0.923.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.85M | 6.52M | 6.24M | 5.37M | 4.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.85M | 6.52M | 6.24M | 5.37M | 4.12M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 4.85M | 6.52M | 6.24M | 5.37M | 4.12M |
| SG&A Expenses | 29.56M | 26.69M | 24.99M | 22.80M | 24.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 134.77M | 123.72M | 108.10M | 88.27M | 72.88M |
| Operating Income | -129.92M | -117.20M | -101.86M | -82.90M | -68.76M |
| Income Before Tax | -114.75M | -100.73M | -84.97M | -67.09M | -56.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -114.75 | -100.73 | -84.97 | -67.09 | -56.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -114.75M | -100.73M | -84.97M | -67.09M | -56.68M |
| EBIT | -129.92M | -117.20M | -101.86M | -82.90M | -68.76M |
| EBITDA | -129.81M | -117.10M | -101.77M | -82.81M | -68.68M |
| EPS Basic | -3.25 | -2.89 | -2.60 | -2.50 | -5.54 |
| Normalized Basic EPS | -2.09 | -1.85 | -1.65 | -1.59 | -3.48 |
| EPS Diluted | -3.25 | -2.89 | -2.60 | -2.50 | -5.54 |
| Normalized Diluted EPS | -2.09 | -1.85 | -1.65 | -1.59 | -3.48 |
| Average Basic Shares Outstanding | 140.88M | 139.29M | 129.16M | 108.95M | 78.62M |
| Average Diluted Shares Outstanding | 140.88M | 139.29M | 129.16M | 108.95M | 78.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |